Insmed (INSM) Chief Medical Officer exercises options and reports stock sales
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Insmed Inc.’s Chief Medical Officer Martina Flammer reported a series of stock transactions. On February 2, 2026, she exercised a stock option for 7,982 shares of common stock at $65.72 per share and sold multiple blocks of common stock under a Rule 10b5-1 trading plan, at weighted average prices including $152.06, $153.16, $154.56, $155.46 and $156.86 per share. On February 3, 2026, she sold 795 shares at $155.77 per share to satisfy tax withholding and related broker fees upon RSU vesting. After these transactions, she directly owned 84,112 shares of common stock and held 23,948 stock options.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 8,777 shares ($1,357,796)
Net Sell
8 txns
Insider
Flammer Martina M.D.
Role
Chief Medical Officer
Sold
8,777 shs ($1.36M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 795 | $155.77 | $124K |
| Exercise | Stock Option (right to buy) | 7,982 | $0.00 | -- |
| Exercise | Common Stock | 7,982 | $65.72 | $525K |
| Sale | Common Stock | 563 | $152.06 | $86K |
| Sale | Common Stock | 928 | $153.16 | $142K |
| Sale | Common Stock | 3,349 | $154.56 | $518K |
| Sale | Common Stock | 3,042 | $155.46 | $473K |
| Sale | Common Stock | 100 | $156.86 | $16K |
Holdings After Transaction:
Common Stock — 84,112 shares (Direct);
Stock Option (right to buy) — 23,948 shares (Direct)
Footnotes (1)
- This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. This is the weighted average sales price representing 563 shares sold at prices ranging from $151.76 to $152.74 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. This is the weighted average sales price representing 928 shares sold at prices ranging from $152.77 to $153.31 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. This is the weighted average sales price representing 3,349 shares sold at prices ranging from $154.10 to $155.09 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. This is the weighted average sales price representing 3,042 shares sold at prices ranging from $155.10 to $155.96 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees. These stock options were granted under the Company's Amended and Restated 2019 Incentive Plan, as amended. The options become exercisable based on the following vesting schedule: 25% vest on the first day of the first month following the first anniversary of the date of grant and an additional 12.5% vest every six months thereafter until fully vested.
FAQ
What insider transactions did INSM Chief Medical Officer Martina Flammer report?
Martina Flammer reported exercising stock options for 7,982 Insmed (INSM) shares and selling several blocks of common stock. Sales occurred at various weighted average prices above $150 per share on February 2–3, 2026, as disclosed in her Form 4 filing.
What stock option exercise did the Insmed (INSM) Form 4 disclose?
The Form 4 shows Martina Flammer exercised a stock option for 7,982 shares of Insmed common stock at an exercise price of $65.72 per share on February 2, 2026. These options were part of the company’s 2019 Incentive Plan and followed a defined vesting schedule.
Was the Insmed (INSM) insider trading under a Rule 10b5-1 plan?
Yes. The filing states the transactions were effected under a Rule 10b5-1 trading plan that Martina Flammer adopted on February 27, 2025. Such plans pre-schedule trades, allowing insiders to systematically sell shares according to predetermined instructions.